The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review

BACKGROUND: Trastuzumab is a monoclonal antibody for patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer, which is added to regular treatment and reduces mortality. Originally, trastuzumab had to be administered intravenously (IV) over 30 min every 3 weeks for 1 year...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Syst Rev
Asıl Yazarlar: Van den Nest, Miriam, Glechner, Anna, Gold, Maria, Gartlehner, Gerald
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2019
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6905114/
https://ncbi.nlm.nih.gov/pubmed/31829250
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13643-019-1235-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller